Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00654654 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases
A Phase 2 study, sponsored by Castle Creek Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00654654 is a Phase 2 study that has completed, run by Castle Creek Biosciences. The registered enrollment target is 50 participants.
The verdict
NCT00654654, a Phase 2 study, has completed, sponsored by Castle Creek Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety profile and the treatment effect of autologous human fibroblasts and placebo when administered to facial wrinkles and creases
Interventions
- BIOLOGICAL Autologous Human Fibroblasts (azficel-T)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00654654
The ClinicalTrials.gov registry entry for NCT00654654 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Castle Creek Biosciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous Human Fibroblasts (azficel-T) is the first listed.
NCT00654654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00654654 about?
NCT00654654 is a clinical study titled "Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases". The purpose of this study is to evaluate the safety profile and the treatment effect of autologous human fibroblasts and placebo when administered to facial wrinkles and creases
What is the current status of trial NCT00654654?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2007-03. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00654654?
The interventions under investigation include: Autologous Human Fibroblasts (azficel-T) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00654654?
This trial is sponsored by Castle Creek Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.